Sign In
Buy CAI
$15.67
-0.420 (-2.61%)
At Close: Jul 31, 2026
Caris Life Sciences Eyes Bigger Oncology Market After IPO as Revenue Jumps 79%
05:06am, Wednesday, 13'th May 2026
Caris Life Sciences NASDAQ: CAI executives said the company is expanding its commercial reach, product pipeline and biopharma partnerships as it looks to build on recent revenue growth following its I
Caris Life Sciences, Inc. (CAI) Presents at Bank of America Global Healthcare Conference 2026 Transcript
03:40pm, Tuesday, 12'th May 2026
Caris Life Sciences, Inc. (CAI) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Targeted gene panels miscalculate tumor mutational burden in 10–15% of patients, directly resulting in incorrect pembrolizumab eligibility determination IRVING, Texas, May 11, 2026 /PRNewswire/ -- C
IRVING, Texas, May 8, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, today announced that it has
Caris Life Sciences, Inc. (CAI) Q1 2026 Earnings Call Transcript
10:41am, Friday, 08'th May 2026
Caris Life Sciences, Inc. (CAI) Q1 2026 Earnings Call Transcript
Caris Life Sciences Reports First Quarter 2026 Financial Results
04:05pm, Thursday, 07'th May 2026
Revenue growth of 79% driven by strong performance in molecular profiling services IRVING, Texas, May 7, 2026 /PRNewswire/ -- Caris Life Sciences, Inc. (Nasdaq: CAI), a leading, patient centric, next-
Caris MI Clarity leverages AI to transform how recurrence risk is understood and applied in postmenopausal patients with HR-positive/HER2-negative, node-negative early-stage breast cancer IRVING, Texa
IRVING, Texas, May 4, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient‑centric, next‑generation AI TechBio company and precision medicine pioneer, today announced that
Capitan Investment Ltd. Announces Appointment of Chief Financial Officer and Chair
12:07pm, Friday, 01'st May 2026
Calgary, Alberta--(Newsfile Corp. - May 1, 2026) - Capitan Investment Ltd. (TSXV: CAI) ("Capitan") announces that effective April 30, 2026, Liqun Hao was appointed the Chief Financial Officer of Capi
Caris Life Sciences Publishes Study Validating Caris AI Insights for Temozolomide Benefit in Glioblastoma Patients
08:30am, Wednesday, 29'th Apr 2026
Caris AI Insights are proprietary and only available to Caris Life Sciences customers IRVING, Texas, April 29, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, nex
IRVING, Texas, April 24, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that
Caris Life Sciences to Report First Quarter 2026 Financial Results on May 7, 2026
08:30am, Monday, 20'th Apr 2026
IRVING, Texas, April 20, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it wi
Caris Precision Oncology Alliance Welcomes UCSF Helen Diller Family Comprehensive Cancer Center
08:30am, Friday, 17'th Apr 2026
IRVING, Texas, April 17, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced tha
Comprehensive molecular profiling paired with biomarker-driven trial matching provides cancer patients with a complete pathway from diagnosis to treatment across more than 600 locations nationwide IRV
Caris Life Sciences: Post-IPO Pullback Creates A Long-Term Buy Opportunity
08:30am, Monday, 13'th Apr 2026
Caris Life Sciences' approach pairs molecular profiling, AI, and large clinico-genomic datasets to support oncology diagnostics, therapy selection, and R&D. Its core platforms are the MI Profile and C
